| Barreto, Andrew D |
SEGA, NCT03263117: SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke |
|
|
| Completed | 4 | 260 | US | Sedation, General Anesthesia (GA), Intra-arterial Thrombectomy, Endovascular Therapy | The University of Texas Health Science Center, Houston, Stryker Neurovascular | Stroke | 04/23 | 04/23 | | |
| Active, not recruiting | 3 | 514 | US | Argatroban, Eptifibatide, Placebo | Washington University School of Medicine, National Institute of Neurological Disorders and Stroke (NINDS) | Acute Ischemic Stroke | 12/23 | 04/25 | | |
| Recruiting | 3 | 700 | US | Apixaban, Eliquis, Aspirin | Yale University, National Institute of Neurological Disorders and Stroke (NINDS) | Intracerebral Hemorrhage, Atrial Fibrillation | 04/27 | 04/27 | | |
| Recruiting | 2 | 300 | US | TS23 | Translational Sciences, Inc., University of Cincinnati, National Institute of Neurological Disorders and Stroke (NINDS), Medical University of South Carolina, University of Arizona | Ischemic Stroke | 07/27 | 12/27 | | |
DoubleDoseTNK, NCT06801054: SAFETY OF A SECOND DOSE OF TENECTEPLASE IN SELECTED ACUTE ISCHEMIC STROKE PATIENTS NOT RESPONDING TO THE FIRST DOSE |
|
|
| Not yet recruiting | 1 | 20 | US | Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) | Memorial Hermann Health System, Grotta Stroke Research Foundation, Memorial Hermann Hospital Mobile Stroke Unit, The University of Texas Health Science Center, Houston | Acute Ischemic Stroke | 02/26 | 04/26 | | |
| McCarthy, James J |
| Completed | 1 | 27 | RoW | UFluA 20 µg each antigen/dose, UFluA 60 µg each antigen/dose, Placebo | Emergent BioSolutions | Human Influenza | 10/23 | 10/23 | | |
HD-MAP, NCT06417853: Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch |
|
|
| Recruiting | 1 | 258 | RoW | Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection, Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Injection, Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, low dose adjuvant), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, high dose adjuvant), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, low dose adjuvant), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, high dose adjuvant), Microarray Patch Delivery System | Vaxxas Pty Ltd, Biomedical Advanced Research and Development Authority | H7N9 Influenza | 05/26 | 05/26 | | |
| Recruiting | N/A | 2000000 | US | Exome sequencing | Helix, Inc, Medical University of South Carolina, HealthPartners Institute, Memorial Hermann Health System, WellSpan Health, St. Luke's Hospital and Health Network, Pennsylvania, Nebraska Medicine - University of Nebraska Medical Center | Genetic Predisposition to Disease, Genetics Disease | 09/31 | 09/36 | | |
| Savitz, Sean I |
SEGA, NCT03263117: SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke |
|
|
| Completed | 4 | 260 | US | Sedation, General Anesthesia (GA), Intra-arterial Thrombectomy, Endovascular Therapy | The University of Texas Health Science Center, Houston, Stryker Neurovascular | Stroke | 04/23 | 04/23 | | |
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis |
|
|
| Recruiting | 3 | 1683 | US | Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management | University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca | Intracranial Arteriosclerosis, Stroke | 05/28 | 05/28 | | |
NCT03915431: A Study of NCS-01 in Patients With Acute Ischemic Stroke |
|
|
| Active, not recruiting | 1/2 | 16 | US | NCS-01 | NC Medial Research Inc | Ischemic Stroke | 10/27 | 10/28 | | |
| Active, not recruiting | N/A | 1892 | US | No interventions | Massachusetts General Hospital, Duke University, Johns Hopkins University, University of New Mexico, University of Southern California, University of Kentucky, Rush University Medical Center, University of Maryland, Baltimore, University of California, San Francisco, University of California, Los Angeles, University of California, Davis, University of Texas, The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center, Houston, Mayo Clinic, University of Mississippi Medical Center, Washington University School of Medicine, Olive View-UCLA Education & Research Institute | Cognitive Impairment, Dementia | 07/27 | 07/27 | | |
| Recruiting | N/A | 9 | US | Treatment | The University of Texas Health Science Center, Houston | Chronic Stroke | 09/26 | 12/26 | | |
| Completed | N/A | 20 | US | Telerehabilitation | The University of Texas Health Science Center, Houston | Stroke | 05/23 | 05/23 | | |
EMAGINE, NCT05044507: The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "" STUDY) |
|
|
| Completed | N/A | 100 | US | BQ 2.0, BQ 2.0 sham stimulation group, BQ 2.0 active stimulation group | BrainQ Technologies Ltd. | Ischemic Stroke | 11/23 | 01/24 | | |
| Completed | N/A | 15 | US | Telerehabilitation (VAST 2) | The University of Texas Health Science Center, Houston, Lone Star Stroke Consortium | Stroke | 01/24 | 01/24 | | |
NS-CIP-001, NCT06288217: Non-invasive Trigeminal and Vagus Nerve Stimulation for Stroke Subjects With Chronic Upper Extremity Deficits |
|
|
| Recruiting | N/A | 25 | US | NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation), nTVNS, Upper Limb Rehabilitation, Sham Stimulation | NeuraStasis, Inc | Stroke, Ischemic, Upper Extremity Paresis | 12/24 | 12/24 | | |
NCT06386874: EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment |
|
|
| Recruiting | N/A | 122 | US | Q Therapeutic System (BQ 3.0) - Sham, BQ 3.0 Sham Stimulation Group, Q Therapeutic System (BQ 3.0) - Active, BQ 3.0 Active Stimulation Group Interventions | BrainQ Technologies Ltd. | Ischemic Stroke | 07/26 | 10/26 | | |
NCT05659875: CompARing Long terM Outcomes in Chronic Stroke Survivors Across Investigational Assessments Following a Prescribed Upper Extremity Exercise Program |
|
|
| Completed | N/A | 1 | US | Standard Occupational Therapy Arm Exercise Program, standard occupational therapy arm exercises | The University of Texas Health Science Center, Houston | Chronic Stroke | 03/24 | 03/24 | | |
VERIFY, NCT05338697: Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials |
|
|
| Recruiting | N/A | 657 | US | Transcranial Magnetic Stimulation (TMS) | University of Cincinnati, University of California, Los Angeles, University of Auckland, New Zealand, Medical University of South Carolina | Stroke, Stroke, Acute, Stroke, Ischemic, Stroke Hemorrhagic | 01/27 | 01/27 | | |
| Recruiting | N/A | 8000 | US | | Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS) | Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment | 11/25 | 11/25 | | |
| Garrett, Jennifer |
AQUAX2, NCT05926765: A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US | AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, Placebo | MeiraGTx, LLC | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands | 07/25 | 07/25 | | |
| Active, not recruiting | 2 | 380 | US | Nicotine Transdermal Patch, Placebo Patch | University of Southern California, National Institute on Aging (NIA), Vanderbilt University, Alzheimer's Therapeutic Research Institute | Mild Cognitive Impairment | 09/25 | 09/25 | | |
| Recruiting | 1/2 | 40 | US | Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram, Ocrelizumab infusion | The Methodist Hospital Research Institute, Genentech, Inc. | Schizo-Affective Type of Psychosis, Schizophrenia | 06/25 | 10/25 | | |
MyPEAK-1, NCT05836259: Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM |
|
|
| Recruiting | 1/2 | 30 | US | TN-201 | Tenaya Therapeutics | Hypertrophic Cardiomyopathy | 08/27 | 08/32 | | |
| Recruiting | 1 | 140 | Europe, US | SEA-CD70, azacitidine, VIDAZA | Seagen Inc. | Myelodysplastic Syndrome, Acute Myeloid Leukemia | 12/24 | 11/26 | | |
| Recruiting | N/A | 125 | US | smaller incision, new generation implantable miniature telescope (SING-IMT) | VisionCare, Inc., ORA, Inc. | Age-Related Macular Degeneration, Geographic Atrophy | 12/25 | 12/25 | | |
NCT05736848: A Retrospective Assessment of OviTex PRS (OviTex) |
|
|
| Recruiting | N/A | 200 | US | OviTex® PRS, OviTex PRS Permanent - Pre-pectoral, OviTex PRS Permanent - Sub-pectoral, OviTex PRS Resorbable - Pre-pectoral, OviTex PRS Resorbable - Sub-pectoral | Tela Bio Inc, MCRA | Reconstructive Surgical Procedures | 07/25 | 12/25 | | |
